Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
| Autor: | Eva Segelov, Zhen Rong Siow, Dev Kevat, David Wyld, Richard Gauci, David Ransom, Amanda Love, Veronica Boyle, Andrew H. Strickland, Sharon Pattison, Marianne S. Elston, Richard W. Carroll, Kim Robyn Kennedy |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Receptors Peptide receptor Pituitary Function Tests Hypopituitarism somatostatin Gastroenterology Growth hormone deficiency Internal medicine medicine Humans hypogonadism Radiology Nuclear Medicine and imaging Receptor RC254-282 Research Articles Aged radioisotopes Somatostatin receptor business.industry Australia Neoplasms. Tumors. Oncology. Including cancer and carcinogens Clinical Cancer Research Radiotherapy Dosage Middle Aged medicine.disease Neuroendocrine Tumors Somatostatin Oncology Radionuclide therapy Cohort Quality of Life Female neuroendocrine tumours business Hormone New Zealand Research Article |
| Zdroj: | Cancer Medicine Cancer Medicine, Vol 10, Iss 23, Pp 8405-8411 (2021) |
| ISSN: | 2045-7634 |
| Popis: | Peptide receptor radionuclide therapy (PRRT) is an increasingly used treatment for unresectable neuroendocrine tumours (NETs) that express somatostatin receptors. Normal pituitary tissue expresses somatostatin receptors so patients receiving PRRT may be at risk of developing hypopituitarism. The aim was to assess the prevalence of clinically significant hypopituitarism a minimum of 2 years following radioisotope therapy for metastatic NET. This was a multicentre study (Australia and New Zealand). Sixty‐six patients with unresectable NETs were included–34 had received PRRT and 32 comparison patients. Median follow‐up after PRRT was 68 months. Male hypogonadism was the most common hormonal abnormality (16 of 38 men [42%]) from the total cohort. Of these, seven men had primary hypogonadism (five from PRRT group) and nine had secondary hypogonadism (six in PRRT group). There was no difference in either male hypogonadism or other hormonal dysfunction between patients who had received PRRT and those that had not. Patients who have received PRRT out to 68 months following treatment do not show concerning hypopituitarism although there may be the suggestion of growth hormone deficiency developing. However, hypogonadism is common in men with NETs so the gonadal axis should be assessed in men with suggestive symptoms as the treatment of testosterone deficiency may improve the quality of life. Graphical representation of physiological pituitary activity on Gallium 68‐DOTA‐Octreotate PET/CT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |